Sex-Specific Differences and How to Handle Them in Early Psoriatic Arthritis

Evangelia Passia
Erasmus Medical Centre: Erasmus MC

Marijn Vis
Erasmus Medical Centre: Erasmus MC

Laura Coates
NDORMS: University of Oxford Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences

Anuska Soni
NDORMS: University of Oxford Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences

Ilja Tchetverikov
Albert Schweitzer Hospital: Albert Schweitzer Ziekenhuis

Andreas Gerards
Franciscus Gasthuis en Vlietland

Marc Kok
Maasstad Hospital: Maasstad Ziekenhuis

Petra Vos
Amphia Hospital: Amphia Ziekenhuis

Lindy-Ann Korswagen
Franciscus Gasthuis en Vlietland

Fouzia Fodili
Reuma Zorg ZuidWest Nederland

Yvonne Ruiterman
Haga Hospital: HagaZiekenhuis

Jos van der Kaap
Admiraal De Ruyter Hospital: Admiraal De Ruyter Ziekenhuis

Maikel van Oosterhout
Groene Hart Hospital: Groene Hart Ziekenhuis

Jolanda Luime (jolanda.luime@mmc.nl)
ErasmusMC https://orcid.org/0000-0002-1071-7932

Keywords: Psoriatic arthritis, Sex differences

DOI: https://doi.org/10.21203/rs.3.rs-434362/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objectives:

The prevalence of Psoriatic Arthritis (PsA) is the same in men and women, however, the latter experience a higher burden of disease and are affected more frequently by polyarthritis. Here, we performed an early PsA cohort analysis to assess sex-related differences in demographics, disease characteristics and evolution over 1 year including applied treatment strategies.

Methods:

Our study is embedded in the Dutch south-west Early Psoriatic Arthritis cohOrt. We described patient characteristics and treatment decisions. For the comparison across sexes and baseline and 1 year follow up, appropriate tests depending on the distribution were used.

Results:

273 men and 294 women with no significant differences in age and ethnicity were included. Women reported significantly longer duration of symptoms before diagnosis and significantly higher tender joint count, a higher disease activity, higher levels of pain and lower functional capacity. Although minimal disease activity (MDA) rates increased over time for both sexes, MDA remained significantly more prevalent among men at one year (58.1% vs 35.7%, \( p<0.00 \)).

Initially, treatment strategies were similar in both sexes with Methotrexate being the most frequently used drug during the first year. Women received Methotrexate for a shorter period \([196(93-364) vs 306(157-365), p<0.00]\) and therefore received a lower cumulative dose compared to men. Retention time was shorter for all DMARDs and women had a delayed start on b-DMARDs.

Conclusion:

After 1 year of standard-of-care treatment women didn't surpass their baseline disadvantages. Despite the overall improvement, they still presented higher disease activity, higher levels of pain and lower functional capacity score than men. The nature of these findings may advocate a need for sex specific adjustment of treatment strategies and evaluation in early PsA patients.

Highlights

What is already known about this subject?

- Although the prevalence of Psoriatic Arthritis is equal between men and women, the burden of disease is higher for women than for men in established disease

What does this study add?

- Differences in disease burden are present from the diagnosis onwards
- Improvement of Disease activity evolves equally for the continuous measures, except for reaching Minimal Disease Activity (MDA). MDA is more often achieved by men
- DMARD frequency and dosing are initially equal, but over time cumulative doses and DMARD retention time were lower in women

How might this impact on clinical practice or future developments?

- The nature of these findings may advocate a need for sex specific adjustment of treatment strategies and evaluation in early PsA patients.

Introduction

Sex and health is a new area of study, aiming to investigate the differences between men and women in both health and disease. Sex has been shown to affect natural history, clinical manifestations and response to medications in several rheumatic diseases. Although the prevalence of Psoriatic Arthritis (PsA) is considered equal in men and women, they are not equally affected, with women experiencing a higher burden of disease (pain, disability and fatigue). [1–4] A few studies though suggested that the prevalence of PsA is higher in men [5–7] and at the same time others have demonstrated the opposite [8, 9]. Differences also seem to exist in clinical expression of PsA with men assembling more peripheral and axial joint impairment and women being affected more frequently by polyarthritis, higher tender joint count and higher scores of functional disability [1–4]. Development of radiographic joint damage is more likely present in men whereas women seem to report lower quality of life [1]. Women are also more likely to present a treatment-resistant PsA disease and compared to men are reported to have higher PsA life impact [10, 11]. According to the international study of Orbai et al. the present treatment protocols seem not adequate to overpass the life impact divergence between men and women.[12]

Sex differences in PsA are not yet embedded in clinical practice or in the scientific thinking as there is little knowledge about clinical expression and disease activity differences by sex in PsA patients. Additional research is needed to explore the impact of sex on clinical expression, disease burden, treatment prescription and response in PsA, something that would improve disease management and contribute to an optimal therapy.
The objectives of our research project are to assess sex-related differences in baseline demographics, disease characteristics and comorbidities in patients with newly diagnosed PsA. Secondly, to evaluate PsA evolution over time (1 year follow up), stratified by sex, for disease activity and health related quality of life. Our further objective is to identify whether there is a diversity of therapeutic decisions between sexes in our cohort in the first year after diagnosis and their relation with the aforementioned findings.

**Methods**

**Patients and setting:**

Our study is embedded in the Dutch south-west Early Psoriatic Arthritis Registry (DEPAR)[13], a prospective cohort study which included newly diagnosed patients with PsA. The diagnosis was made by rheumatologists and based on expert opinion; no classification criteria were applied to ensure enrollment of a population representative of daily clinical practice. For this analysis, data were used from patients included between August 2013 and February 2019 recruited in centers in the southwest of the Netherlands (1 academic and 10 general hospitals, 1 treatment center specialized in rheumatic care). Patients who participated provided a written informed consent according to the Declaration of Helsinki. Local medical research ethics committee of Erasmus University Medical Center of Rotterdam authorized the study.

**Data collection:**

Information for newly diagnosed patients with PsA was collected every three months during the first year after diagnosis. DEPAR cohort’s research nurses collected clinical information, medical records and carried out clinical examination. Patients also completed a broad spectrum of Patient Reported Outcome Measures (PROMs) before each appointment with nurses.

**Patient and disease characteristics, disease activity measures:**

We evaluated the health status and the impact of PsA to the patients with newly diagnosed PsA using patient’s global and pain scores on a visual analogue scale (VAS), fatigue using the Bristol Rheumatoid Arthritis Fatigue (BRAF) questionnaire [14], health-related quality of life (HRQoL) by the Hospital Anxiety and Depression Scale (HADS) [15] and the Short Form 36 Health Survey (SF-36) presented by the Physical Component Summary (PCS) and Mental Component Summary (MCS) [16]. The functional status of the PsA patients was evaluated using the Health Assessment Questionnaire (HAQ) [17]. We evaluated the skin disease of the patients who presented concomitant PsA and psoriasis using the Psoriasis Area and Severity Index (PASI) score [18] and the impact using the Skindex-17 questionnaire [19].

We measured disease activity using activity parameters commonly used in clinical practice and research for patients diagnosed with PsA: Minimal disease ActivityMDA [20], GRAppa Composite ScorE (GRACE)[21], Psoriatic Arthritis Disease Activity Score (PASDAS)[22], Disease Activity Psoriatic Arthritis (DAPSA) and Composite Psoriatic Disease Activity Index (CPDAI)[23].

**Statistical analysis**

Patient characteristics are described using simple descriptive analysis techniques, with continuous variables summarized by their means (and SD) or medians (and IQR) and categorical variables summarized by their proportions. For the unadjusted comparison across men and women, Pearson's Chi2-test was used for categorical variables and t-test was used to compare continuous variables that are normally distributed whereas Kruskal-Wallis was used for continuous variables that are not normally distributed. A p < 0.05 is considered statistically significant.

Comparisons at baseline and at 1-year follow-up and between subgroups (men, women) were performed with Pearson's Chi2-test and Kruskal-Wallis test. Difference in evolution over time of continuous variables between the sexes was tested by difference in slope using the partial derivative of the response with respect to time separately by sex of a linear mixed models (LMM) in which time and sex interacted. Binary measures were analyzed using Logistic mixed models to account for repeated measures over time (MDA). Five timepoints were used: baseline, 3, 6, 9 and 12 months after diagnosis.

Simple descriptive analysis techniques were also used in order to describe the therapeutic decisions and their differences between sexes. As many different strategies were used, both in type of drug, combination of drugs as well as dosing we decided to simplify medication use. To be able to see differences in transitions of drugs over time between the sexes we categorized the DMARDs in most potent drug categories: b-DMARDs, Methotrexate, cs-DMARDs (other than Methotrexate), GCs (Glucocorticosteroids) and no-DMARDs. Missing values of any type of dependent or independent variables were not imputed as all patients were included from their initial moment of participating with available data independent whether they had a complete 1-year of follow-up.

Statistical analyses were performed using STATA-16.

**Results**

**Sex-related differences in baseline demographics, disease characteristics and comorbidities between men and women with newly diagnosed PsA:**

In February 2019, out of 620 patients who participated in DEPAR cohort, a total of 307 men and 313 women were available for analysis. Both groups were similar regarding ethnicity and smoking. There were no differences across men and women in the age at onset of PsA; however, women reported longer duration of symptoms before diagnosis of PsA (11 vs 7.4 months, \( p < 0.00 \)). Years of daytime education as proxy for educational level was one year \( p < 0.05 \)
less in women (12; IQR 10–15) compared to men (13; IQR 11–16) and fewer women than men were in paid employment (64% vs 78%, \( p < 0.00 \)). The prevalence of obesity (BMI >30kg/m²) was higher in women than in men (36% versus 28%, \( p < 0.05 \)).

Oligoarthritis was the predominant pattern of arthritis in both men and women but with a significantly higher prevalence in men (45.9% in men vs 34.2% in women, \( p < 0.05 \)). Polyarthritis was more prevalent in women (25.4% in women versus 19.6% in men), but this difference was not statistically significant. Clinically defined enthesitis had a significantly higher prevalence in women than in men (14.3% vs 5.9% in men, \( p < 0.05 \)). There was a significantly higher proportion of women with axial disease as first manifestation of PsA, however the small sample size available may affect the reliability of this result (Graph 1).

Women presented at baseline higher tender joint count than men (TJC68 : 4 vs 2, \( p < 0.00 \)) whereas there was no difference in swollen joint count (SJC66). All composite indices studied (CPDAI, DAPSA, GRACE, MDA, PASDAS) showed significantly worse results in women at baseline (Table 1). There was no statistically significant difference of absolute CRP levels although CRP was positive (>5mg/L) in 41% of men and 30% of women (\( p < 0.05 \)).

| Table 1: Patient Characteristics at Baseline by Sex |
|---------------------------------|--------|--------|
|                                | all    | men    | women  |
| Age at onset of PsA*           | 50 (39–60) | 50 (40–61) | 51 (38–60) |
| Duration of symptoms (months)* | 11 (3.6–33.3) | 7.4 (3.2–25.6) | 13.5 (4.6–44.8) |
| Working status (age <68), yes**| 71%    | 78%    | 64%    |
| Educational status (years)*    | 12 (10–15) | 13 (11–16) | 12 (10–15) |
| Ethnicity (Dutch)**            | 94%    | 94%    | 93%    |
| Smoking, yes**                 | 21%    | 18%    | 24%    |
| BMI*                           | 27.5 (25.3–31.4) | 27.2 (24.8–31.1) | 27.9 (24.3–31.7) |
| Obesity (BMI >30kg/m²)         | 32%    | 28%    | 36%    |
| CRP (mg/L)*                    | 3.9 (0–10) | 4 (0.8–11) | 3.4 (0–9) |
| CRP positive (>5mg/L)          | 36%    | 41%    | 30%    |
| SJC66*                         | 2 (1–4) | 2 (1–4) | 2 (0–4) |
| TJC68*                         | 3 (1–7) | 2 (1–5) | 4 (2–8) |
|VAS global*                     | 47 (24–65) | 40 (19–58) | 51 (31–70) |
| Pain (VAS score)*              | 47 (25–69) | 41 (21.5–62) | 53 (31–71) |
| PASI*                          | 2 (0.4–4.4) | 2.4 (0.6–5.2) | 1.45 (0.3–3.45) |
| Anxiety**                      | 4 (2–7) | 4 (1–6) | 5 (3–8) |
| BRAF*                          | 20 (10–31) | 16 (6–27) | 25 (15–34) |
| HAQ*                           | 0.75 (0.38–1.13) | 0.63 (0.19–0.88) | 0.88 (0.50–1.25) |
| CPDAI*                         | 4 (2–5) | 3 (2–5) | 4 (3–6) |
| DAPSA*                         | 21 (13–32) | 19 (11–32) | 22 (15–32) |
| GRACE*                         | 3.4 (2.3–4.3) | 3.0(2.0–4.3) | 3.6(2.6–4.5) |
| MDA**                          | 31%    | 30%    | 32%    |
| PASDAS***                      | 4.2 (3.3–4.9) | 4 (3.1–4.8) | 4.3 (3.5–5) |

Skin lesions were more prevalent in men. Although women were more likely to report a positive family history of psoriasis, men presented significantly higher PASI score (2.4 (IQR 0.6–5.2) versus 1.5 (IQR 0.3–3.5) in women.

Women presented more frequently fatigue, anxiety, and comorbid medical conditions (chronic inflammatory diseases). At baseline, women suffered more severe limitations in function and worse quality of life compared with men based in all patients’ reported outcomes. (Table 1).

PsA evolution over 1 year of follow up, stratified by sex :
Among the 108 patients (19% of the DEPAR population) that did not yet complete the 12 month follow-up or dropped out, 53 (19.4% of men population) were men and 55 (18.7% of women population) were women. Overall, there were no statistically significant differences between sexes concerning the reason and the timing of discontinuation before T12 (Supplementary Table 1a,b).

The composite disease activity measures studied (CPDAI, GRACE, PASDAS, DAPSA) presented also similar pattern of evolution through the year for both men and women (Fig. 2), however they were significantly higher in women at both time points (Table 1, 2 and Supplementary Fig. 2). MDA, although its progressive beneficial change through time for both sexes (Fig. 2), remained predominantly present among men (18.0% vs 10% at inclusion, p < 0.05, and 59% vs 37%, p < 0.00, at 1-year follow-up). Furthermore, DAPSA remission, the other treatment target in PsA [24], showed a significantly higher percentage of men (28% vs 11% of women, p < 0.00) presented remission according to DAPSA (≤4) at 12 months of follow up.

Table 2  Patient characteristics stratified on sex at 1-year follow up (T12).

| Characteristic | men (n = 220) | women (n = 233) | p < 0.05 |
|----------------|-------------|----------------|---------|
| Laboratory values |             |                |         |
| CRP            | 2 (0–4.9)   | 2 (0–5)        | #       |
| CRP > 5mg (%)  | 13          | 16             |         |
| Clinical assessment |        |                |         |
| TJC 68         | 0 (0–2)     | 1 (0–4)        | #       |
| SJC 66         | 0 (0–1)     | 0 (0–1)        |         |
| PASI           | 1.2 (0.2–8) | 0.45 (0.1–8)   | #       |
| Patient questionnaire |       |                |         |
| VAS global     | 18 (5–37)   | 29 (12–51)     | #       |
| VAS pain       | 16 (4.5–40)| 31 (12–60)     | #       |
| HAQ            | 0.13 (0.063)| 0.75 (0.25–1.1)| #       |
| Skindex-17 - symptoms | 3 (1–4)| 3 (1–5)      | #       |
| Skindex-17 - psychosocial | 0 (0–3)| 0 (0–3)       |         |
| SF36-PCS       | 48 (39–53)  | 42 (35–47)     | #       |
| SF36-MCS       | 54 (46–59)  | 48 (40–55)     | #       |
| BRAF           | 13 (6–22)   | 22 (15–32)     | #       |
| Composite measures |         |                |         |
| CPDAI          | 1 (1–2)     | 2 (1–4)        | #       |
| DAPSA          | 7.5 (3.3–15)| 13 (6.8–22)    | #       |
| GRACE          | 1.4 (0.6–2.7)| 2.3 (1.3–3.6)| #       |
| MDA, yes (%)   | 59          | 37             | #       |
| PASDAS         | 2.2 (1.6–3.3)| 3 (2.1–4)     | #       |

#p < 0.05, Fischer’s exact test

Swollen joint count showed statistically significant improvement in both men and women at 1 year follow up (Table 2). Both groups presented improvement of CRP at the end of the 1st year. Interestingly, the percentage of women with positive CRP (CRP > 5mg/l) remained high at 1 year follow up (28.8% at inclusion and 21.4% at 1 year follow up, p = 0.06).

Women, despite the improvement that they presented through one year follow up, reported higher levels of pain (VAS) compared to men at 1 year follow up (16 vs 31, p < 0.00). Similarly, HAQ improved through time for both men and women but remained statistically higher in the latter (Table 2). BRAF score (corresponding to fatigue) shows a limited beneficial change through time for both men and women (Table 2).

**Therapeutic decisions in DEPAR cohort, by sex:**

At baseline, 54% of the women and 56% of the men started with Methotrexate, 12% of the women and 6% of men started another cs-DMARD, while 2% of the women and 6% of the men used an b-DMARD. This early use or start of b-DMARDs was either due to patients already using them, axial disease or the prior use of Methotrexate in Psoriasis that did not prevent onset of arthitis. In 32% of the females and 33% of the men no DMARD was prescribed, while 1% of the women and 2% of the men used a GCs only.
Over time different treatment strategies were followed as shown in Table 3. Here, we present the most remarkable differences in the frequency of the most dominant DMARD and also in total exposure to the different DMARDs expressed in cumulative doses for the cs-DMARDs and in number of days for the b-DMARDs. After 3 months, 77% of the women retained their Methotrexate as dominant drug, 10% of the women refrained from any DMARD, 6% was changed to another cs-DMARD, 6% to a b-DMARD, while another 1% only used GCs. This compared to men of who 88% kept their Methotrexate, 7% changed to no-DMARDs, 4% to another cs-DMARD and 1% to a biological. Over the subsequent 3-months intervals of the follow-up, the patterns of change became more comparable between men and women with most patients staying in the same drug category as they were already in. At 12 months the use of Methotrexate had decreased in both sexes to 41%, while no-DMARD use had increased to 34%. b-DMARD use increased to 13% and another 13% of the women and 10% of the men used cs-DMARDs.

Table 3
Dominant drug type and transition of drug type over 3 months intervals stratified for women and men

| Timepoint | Previous DMARD use | Methotrexate | Steroids | cs-DMARDs | b-DMARDs | no DMARD | Methotrexate | Steroids | cs-DMARDs | b-DMARDs | None |
|-----------|--------------------|--------------|----------|------------|----------|-----------|--------------|----------|------------|----------|------|
| Baseline  |                    | 54%          | 1%       | 12%        | 2%       | 32%       | 56%          | 2%       | 4%         | 4%       | 33%  |
| T3        | Methotrexate       | 77%          | 1%       | 1%         | 10%      | 10%       | 88%          | 2%       | 4%         | 1%       | 7%   |
|           | Steroids           | 50%          | 50%      | 63%        | 40%      | 40%       | 20%          | 18%      | 65%        | 18%      |      |
|           | cs-DMARDs          | 17%          |          | 63%        | 40%      | 40%       | 20%          | 18%      | 65%        | 18%      |      |
|           | b-DMARDs           |              |          | 100%       | 100%     | 100%      | 100%         |          |            |          |      |
|           | none               | 13%          | 4%       | 84%        | 11%      | 1%        | 1%           | 87%      |            |          |      |
| T6        | Methotrexate       | 88%          | 5%       | 3%         | 4%       | 82%       | 1%           | 2%       | 6%         | 9%       |      |
|           | Steroids           | 50%          | 50%      | 100%       |          |           |              |          |            |          |      |
|           | cs-DMARDs          | 13%          | 81%      | 6%         | 5%       | 79%       | 5%           | 11%      |            |          |      |
|           | b-DMARDs           | 13%          | 73%      | 13%        | 7%       | 79%       | 5%           | 11%      |            |          |      |
|           | none               | 10%          | 5%       | 3%         | 81%      | 9%        | 1%           | 1%       | 1%         | 87%      |      |
| T9        | Methotrexate       | 69%          | 12%      | 6%         | 13%      | 78%       | 5%           | 6%       | 12%        |          |      |
|           | Steroids           |              |          | 100%       | 25%      | 25%       | 25%          | 25%      |            |          |      |
|           | cs-DMARDs          | 11%          | 78%      | 11%        | 72%      | 11%       | 17%          | 11%      |            |          |      |
|           | b-DMARDs           | 22%          | 72%      | 6%         | 5%       | 79%       | 16%          |          |            |          |      |
|           | none               | 7%           | 2%       | 5%         | 87%      | 4%        | 3%           | 93%      |            |          |      |
| T12       | Methotrexate       | 79%          | 3%       | 7%         | 11%      | 83%       | 1%           | 6%       | 3%         | 7%       |      |
|           | Steroids           |              |          | 100%       | 100%     | 100%      | 100%         |          |            |          |      |
|           | cs-DMARDs          | 15%          | 56%      | 15%        | 15%      | 6%        | 67%          | 11%      | 17%        |          |      |
|           | b-DMARDs           | 5%           | 86%      | 10%        | 4%       | 85%       | 12%          |          |            |          |      |
|           | none               | 13%          | 6%       | 1%         | 80%      | 12%       | 1%           | 5%       | 1%         | 80%      |      |

* cs-DMARD: conventional synthetic DMARDS excluding Methotrexate
the physicians should be aware of pain being reported differently by man and woman in disease management, since most disease activity measures contain
decisions and introduce sex bias in prescribing. Therefore, pain reported by women should receive specific attention by attending physicians. Furthermore,
is worrisome that women reporting more pain than men may contribute to underdiagnosis or late recognition of symptoms in women, influence management
frequently than men, whilst studies using experimentally induced pain models demonstrate increased pain sensitivity to painful stimuli in women (27, 28). It
women remained higher compared to men at the end of one year of follow up. Population-based research in pain has shown that women report pain more
duration of symptoms before diagnosis and fewer of them were in paid employment. Oligoarthritis was the predominant pattern of arthritis in both sexes.

In our study we observed that women reported higher levels of pain at the time of diagnosis but also, despite the improvement, the levels of pain reported in
women remained higher compared to men at the end of one year of follow up. Population-based research in pain has shown that women report pain more
frequently than men, whilst studies using experimentally induced pain models demonstrate increased pain sensitivity to painful stimuli in women (27, 28). It
is worrisome that women reporting more pain than men may contribute to underdiagnosis or late recognition of symptoms in women, influence management
decisions and introduce sex bias in prescribing. Therefore, pain reported by women should receive specific attention by attending physicians. Furthermore,
the physicians should be aware of pain being reported differently by man and woman in disease management, since most disease activity measures contain

| Table 4 |
| Days, cumulative dose and dose of DMARDs the 1st year after diagnosis stratified for men and women |

|            | Men (n = 304) | Women (n = 311) |
|------------|--------------|-----------------|
| Biological |              |                 |
| days       | p50          | p75             |
| Biological | 42           | 106             |
| Methotrexate| 216         | 208             |
| days       | 216          | 208             |
| cumulative dose (mg) | 541 | 809 |
| Methotrexate | 208     | 208             |
| cumulative dose (mg) | 365 | 365 |
| Leflunomide | 11         | 22              |
| days       | 1740         | 1971            |
| cumulative dose (mg) | 69200 | 615600 |
| Sulfasalazine | 1149  | 149             |
| days       | 258000       | 281000          |
| cumulative dose (mg) | 549500 | 540800 |
| Hydroxychloroquine | 22       | 24              |
| days       | 1740         | 1971            |
| cumulative dose (mg) | 69200 | 615600 |
| Prednisone | 32          | 34              |
| days       | 1740         | 1971            |
| cumulative dose (mg) | 69200 | 615600 |
| Prednisone | 8           | 11              |
| days       | 1740         | 1971            |
| cumulative dose (mg) | 69200 | 615600 |

*non-parametric comparison between men and women

Cumulative doses and drug survival/retention time differed between men and women in first year after diagnosis. Our analysis showed no statistically
significant differences between sexes concerning the 1st dose of the 1st prescribed treatment. However, when analyzing cumulative doses and total period of
the prescribed treatment, we observed a statistically significant difference between sexes regarding the cumulative dose of Methotrexate. More specifically,
during the first year after diagnosis, men received a higher cumulative dose of methotrexate (757mg vs 543mg, men versus women respectively, p < 0.00) and
for a prolonged period of time (306 days (I) vs 196 days (I); p < 0.00). Similar results were observed for the prescription of Methotrexate subcutaneous
injection (557mg (I) vs 365mg (I) p < 0.00 and 183 days (I) vs 166 days (I) p < 0.05). Women treated with Sulfasalazine received also lower cumulative dose
and for a shorter period of time compared to men ([548 gr (I) vs 216 gr, p < 0.00 and 276 (I) vs 108 days (I), p < 0.00]). We observed no differences in daily or
weekly dose for the above mentioned DMARDs, neither did we for the cumulative dose and/or duration of prescription of the other cs-DMARDs or
Glucocorticoids. For the b-DMARDs we saw an earlier start for men compared to women and, likely due to that, a lower number of days exposed for women
although this was not statistically significant.

DMARD side-effects were reported for 198 patients, more for women (58%) than for men (42%). About 38% were reported in the first 3 months, followed by
26–17% in the subsequent 3-month intervals. Methotrexate was most frequently mentioned with 84%, followed by Sulfasalazine, 16%, and Leflunomide, 9%.
Both sexes experienced equally side-effects for Methotrexate and Adalimumab, but side-effects for the other drugs were more often reported by women.

**Discussion**

Symptoms, disease presentation and treatment strategies in early PsA differed between men and women in the first year of disease. Women reported longer
duration of symptoms before diagnosis and fewer of them were in paid employment. Oligoarthritis was the predominant pattern of arthritis in both sexes.
Polyarthritis and enthesitis were more prevalent in women who also presented at baseline with a higher tender joint count than men, but no difference in
swollen joint count. With the exception of DAS28CRP, all composite indices (CPDAI, DAPSA, GRACE, MDA, PASDAS) showed significantly worse results in
women. Cumulative doses and DMARD retention time differed between men and women in first year after diagnosis, although there were no differences in
1st dose of the 1st prescribed treatment. Women were more often switched to cs-DMARDs, and had a delayed start on b-DMARDs.

In our study we observed that women reported higher levels of pain at the time of diagnosis but also, despite the improvement, the levels of pain reported in
women remained higher compared to men at the end of one year of follow up. Population-based research in pain has shown that women report pain more
frequently than men, whilst studies using experimentally induced pain models demonstrate increased pain sensitivity to painful stimuli in women (27, 28). It
is worrisome that women reporting more pain than men may contribute to underdiagnosis or late recognition of symptoms in women, influence management
decisions and introduce sex bias in prescribing. Therefore, pain reported by women should receive specific attention by attending physicians. Furthermore,
the physicians should be aware of pain being reported differently by man and woman in disease management, since most disease activity measures contain
pain and quality of life measurement metrics that may perform differently by sex. Also, the impact of pain on disability indices may be less pronounced in men due to their greater muscle strength, making it easier to perform daily tasks. Muscle strength has been shown to significantly affect the HAQ in patients with Rheumatoid Arthritis (RA)(29). That being said the differences between men and women observed are not only related with differences in pain but could also be related with differences in underlying inflammation, hormonal changes, genetic or other factors, physical activity that need additional research.

In our study we observed that initially no different treatment regimens were followed across sexes, however for specific drugs (methotrexate, sulfasalazine, adalimumab) retention time and cumulative doses were lower in women despite the higher disease burden observed in the later at diagnosis. The fact that women reported more frequently side effects compared to men could be a potential explication for the above-mentioned differences in prescription.

Overall, women in the DEPAR cohort presented higher disease activity, pain and functional impairment compared to men at baseline but also at one year of follow up. Although, similar therapeutic approaches in men and women are followed, in some cases women seem to remain undertreated. The nature of these findings could suggest that sex bias in prescribing exists and may advocate the need for sex specific adjustment of treatment strategies and evaluation of PsA.

Strengths of our study consist the large population with early PsA included in our cohort, well recorded medication use and the regular follow up visits. Only a few studies have focused on early PsA and, to our knowledge, our study is the only one that focuses in sex specific differences in early PsA.

Our study has some limitations. The assessments used in order to detect the differences between sexes were a mix of objective (CRP/SJC), semi-objective (disease activity measures) and subjective tools (e.g. pain score, fatigue). More objective assessments such as MRI or radiographic findings would be useful in order to explain the observed differences between sexes. We were not able to distinguish other conditions that may impact pain and function and are not associated with PsA (e.g. fibromyalgia).

Further studies are required to assess the evolution of these differences over time but also identify the underlying mechanisms (e.g. genetic, hormonal or others) that lead to the observed divergence between men and women with newly diagnosed PsA. Moreover, further research is required to analyze the role of sex on treatment response to PsA and develop treatment strategies to improve PsA management for both sexes in daily clinical practice.

**Conclusion**

After 1 year of follow-up standard-of-care treatment women didn't surpass their baseline disadvantages and despite the improvement, they still present higher disease activity, higher levels of pain and lower functional capacity score than men. The nature of these findings may advocate a need for sex specific adjustment of treatment strategies and evaluation in early PsA patients.

**Abbreviations List**

| Abbreviation | Full Form |
|--------------|-----------|
| CPDAI        | Composite Psoriatic Disease Activity Index |
| CRP          | C-reactive protein |
| DAPSA        | Disease Activity index for Psoriatic Arthritis |
| DAS28        | Disease Activity Score 28 |
| DEPAR        | Dutch south-west Early Psoriatic Arthritis cohort |
| ESR          | Erythrocyte Sedimentation Rate |
| GRACE        | GRAppa Composite ScorE |
| HAQ          | Health Assessment Questionnaire |
| IQR          | Interquartile Range |
| LMM          | Linear Mixed |
| MDA          | Minimal Disease Activity |
| PsA          | Psoriatic Arthritis |
| SD           | Standard Deviation |
| PASDAS       | Psoriatic Arthritis Disease Activity Score |
| PASI         | Psoriasis Area and Severity Index |
| SF36MCS      | Short Form 36 Mental Component Scale |
| SJC66        | Swollen Joint Count |
Declarations

Ethics approval and consent to participate

Patients who participated provided a written informed consent according to the Declaration of Helsinki. Local medical research ethics committee of Erasmus University Medical Center of Rotterdam authorized the study (MEC-2012-549).

Consent for publication Not applicable

Data availability statement We are open to collaboration using DEPAR data for scientific purposes in line with the primary purpose of our cohort. To do so please send a request to the corresponding author, briefly describing the research question and data elements you would like to use. Our scientific committee determines whether the request will be granted.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Competing interests The authors declare that they have no competing interests

Funding No funding was used for this paper. The DEPAR cohort received funding from the Dutch Government via ZON-MW, from the Dutch insurers their Innovation fund, Pfizer via an Investigator initiated start up grant and UCB via their support of the DEPAR cohort.

Authors’ contributions EP and J.J.L analyzed and interpreted the patient data regarding sex differences in Psoriatic Arthritis. M.V took care of the clinical perspective and reviewed the first versions of the paper. All authors read and approved the final manuscript.

Acknowledgement The authors would like to thank the participating patients, research nurses and doctors for acquiring the data. Specific thanks to Maarten de Wit and Wendy Olsder, both patient research partners, for their thoughts on and their interpretation of the very early results of data analysis that lead to this paper.

References

1. Eder L, Thavaneswaran A, Chandran V, Gladman DD: Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. *Annals of the rheumatic diseases* 2013, 72(4):578-582.
2. Queiro R, Tejon P, Coto P, Alonso S, Alperi M, Sarasqueta C, Gonzalez S, Martinez-Borra J, Lopez-Larrea C, Ballina J: Clinical differences between men and women with psoriatic arthritis: relevance of the analysis of genes and polymorphisms in the major histocompatibility complex region and of the age at onset of psoriasis. *Clinical & developmental immunology* 2013, 2013:482691.
3. Queiro R, Sarasqueta C, Torre JC, Tinture T, Lopez-Lagunas I: Comparative analysis of psoriatic spondyloarthropathy between men and women. *Rheumatology international* 2001, 21(2):66-68.
4. Duruoz MT, Gezer HH, Nas K, Kilic E, Sargin B, Kasman SA, Alkan H, Sahin N, Cengiz G, Cuzdan N et al. Gender-Related Differences in Disease Activity and Clinical Features in Patients with Peripheral Psoriatic Arthritis: A Multi-Center Study. *Joint Bone Spine* 2021:105177.
5. Koo T, Nagy Z, Sesztak M, Ujfalussy I, Merete Y, Bohl M, Forgacs S, Szilagyi M, Czirjak L, Farkas V: Subsets in psoriatic arthritis formed by cluster analysis. *Clinical rheumatology* 2001, 20(1):36-43.
6. Trontzas P, Andrianakos A, Miyakis S, Pantelidou K, Vafiadou E, Garantziotou V, Voudouris C: Seronegative spondyloarthopathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. *Clinical rheumatology* 2005, 24(6):583-589.
7. Nossent JC, Gran JT: Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. *Scandinavian journal of rheumatology* 2009, 38(4):251-255.
8. Love TJ, Gudbjornsson B, Gudjonsson JE, Valdimarsson H: Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. *The Journal of rheumatology* 2007, 34(10):2082-2088.
9. Alenius GM, Jidell E, Nordmark L, Rantapaa Dahlqvist S: Disease manifestations and HLA antigens in psoriatic arthritis in northern Sweden. *Clinical rheumatology* 2002, 21(5):357-362.
10. Hojgaard P, Ballegaard C, Cordtz R, Zobke B, Clausen M, Gintborg B, Kristensen LE, Dreyer L: Gender differences in biologic treatment outcomes—a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. *Rheumatology (Oxford, England)* 2018, 57(9):1651-1660.
11. Orbae AM, Perin J, Gorlier C, Coates LC, Kilz T, Leung YY, Palominos PE, Canete JD, Scrivo R, Balanescu A et al: Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association with Gender in 458 Patients from 14 Countries. *Arthritis care & research* 2019.
12. Leung YY, Orbai AM, de Wit M, Balanescu A, Demis E, Soubrier M, Eder L, Smolen JS, Coates LC, Gossec L et al. Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis. *Arthritis Care Res (Hoboken)* 2021, 73(4):593-602.

13. Kasiem FR, Luime JJ, Vis M, Kok MR, Wervers K, Gerards AH, Appels C, van der Graaff WL, Starmans-Kool M, Goekoop-Ruiterman Y et al. Lessons learned from clinical phenotypes in early psoriatic arthritis: the real-world Dutch south west Early Psoriatic Arthritis study. *Scand J Rheumatol* 2020:1-8.

14. Nicklin J, Cramp F, Kirwan J, Greenwood R, Urban M, Hewlett S. Measuring fatigue in rheumatoid arthritis: a cross-sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales. *Arthritis care & research* 2010, 62(11):1559-1568.

15. Zigmond AS, Snaith RP: *The hospital anxiety and depression scale*. *Acta psychiatrca Scandinavica* 1983, 67(6):361-370.

16. Ware JE, Jr., Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Medical care* 1992, 30(6):473-483.

17. Fries JF, Spitz P, Kraines RG, Holman HR: Measurement of patient outcome in arthritis. *Arthritis and rheumatism* 1980, 23(2):137-145.

18. Fredriksson T, Pettersson U: Severe psoriasis--oral therapy with a new retinoid. *Dermatologica* 1978, 157(4):238-244.

19. Nijsten TE, Sampogna F, Chren MM, Abeni DD: Testing and reducing skindex-29 using Rasch analysis: Skindex-17. *The Journal of investigative dermatology* 2006, 126(6):1244-1250.

20. Coates LC, Fransen J, Helliwell PS: Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. *Annals of the rheumatic diseases* 2010, 69(1):48-53.

21. Helliwell PS, FitzGerald O, Fransen J: Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. *The Journal of rheumatology* 2014, 41(6):1212-1217.

22. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R et al: The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). *Annals of the rheumatic diseases* 2013, 72(6):986-991.

23. Mumtaz A, Gallagher P, Kirby B, Waxman R, Coates LC, Veale JD, Helliwell P, FitzGerald O: Development of a preliminary composite disease activity index in psoriatic arthritis. *Annals of the rheumatic diseases* 2011, 70(2):272-277.

24. Smolen JS, Schols M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis.* 2018;77(1):3-17.

25. Queiro-Silva R, Torre-Alonso JC, Tinture-Eguren T, Lopez-Lagunas I. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis. *Annals of the rheumatic diseases*. 2003;62(1):68-70.

26. Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. *British journal of anaesthesia*. 2013;111(1):52-8.

27. Craft RM. *Modulation of pain by estrogens*. *Pain*. 2007;132 Suppl 1:S3-12.

28. Hakkinen A, Kautiainen H, Hannonen P, Ylinen J, Makinen H, Sokka T: Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. *Annals of the rheumatic diseases*. 2006;65(1):30-4.

**Figures**
Figure 1

Phenotypes at Baseline by Sex.
Figure 2

Comparison of evolution of disease activity over time between de sexes as expressed in mean change from baseline

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFile.docx